Search

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Friday, October 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Luis Alberto Diaz, Jr. Appointed to the National Cancer Advisory Board by President Biden Luis Alberto Diaz, Jr. Luis Alberto Diaz, Jr., MD , Head of the Division of Solid Tumor Oncology

Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive leadership team since 2011, most recently serving as Executive Vice President and Chief Operating Officer.

… Monday, June 26, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced that Shelly Anderson, MPM, will join the institution as the inaugural Hospital President on September 25. Anderson joins MSK from Brigham and Women’s Hospital (BWH) in Boston, where she has been a member of the executive

The event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

… Friday, March 19, 2021 On March 17, 2021, scientists from around the world tuned in to watch the 2nd Annual Kravis WISE Symposium , a series of scientific talks sponsored by the Marie-Josée Kravis Women in Science Endeavor (WISE) at Memorial Sloan Kettering. Launched in 2020, Kravis WISE is devoted to

The Tri-Institutional Stem Cell Initiative, comprised of three leading New York City biomedical research institutions -- Memorial Sloan Kettering Cancer Center, The Rockefeller University, and Weill Medical College of Cornell University -- has announced the first wave of stem cell research projects to be funded through a $50 million gift from The Starr Foundation.

… Monday, July 31, 2006 First Research Projects to be Funded under the Tri-Institutional Stem Cell Initiative The Tri-Institutional Stem Cell Initiative , comprised of three leading New York City biomedical research institutions — Memorial Sloan Kettering Cancer Center, The Rockefeller University, and

A collaborative team from MSK has uncovered important new findings that explain why ovarian cancer does not respond to immunotherapy.

… Wednesday, December 14, 2022 A team at Memorial Sloan Kettering Cancer Center (MSK) has uncovered several mechanisms of immune escape that can help explain why ovarian cancers have been resistant to immunotherapy to date. The researchers found that ovarian cancer is even more complex than previously

Cell replacement therapy seeks to restore function in the body by replacing cells that are lost due to disease or injury with new, healthy cells. One disease for which this type of therapy holds particular promise is the degenerative neurological disorder Parkinson’s disease, which is characterized by symptoms related to movement.

… Tuesday, August 21, 2012 Summary Cell replacement therapy seeks to restore function in the body by replacing cells that are lost due to disease or injury with new, healthy cells. One disease for which this type of therapy holds particular promise is the degenerative neurological disorder Parkinson’s

Studies conducted in mice reveal a potential way to breach the defenses of pancreatic cancer tumors.

… Tuesday, March 31, 2020 Summary In a study published March 31, researchers at the Sloan Kettering Institute report that a two-drug combination makes pancreatic cancer more sensitive to immunotherapy in mouse models. Pancreatic cancer is one of the most challenging cancers to treat. In part, that’s because

Learn how highly focused, intense radiation can stop lung cancer from growing after it has spread to a small number of sites.

… Thursday, December 14, 2023 Non-small cell lung cancer (NSCLC) , the most common form of lung cancer , is often diagnosed at an advanced  stage . About half the time, it has already spread around the body and has reached stage 4. The standard treatment for most patients with metastatic NSCLC is systemic

Obtenga información sobre cómo la radiación intensamente focalizada y de alta dosis puede detener el crecimiento del cáncer pulmonar después de que se ha diseminado a una pequeña cantidad de sitios.

… Thursday, December 14, 2023 El cáncer pulmonar de células no pequeñas (CPCNP) , la forma más común de cáncer pulmonar , suele diagnosticarse en un estadio  avanzado . Aproximadamente la mitad de las veces, ya se ha diseminado por el cuerpo y ha alcanzado el estadio 4. El tratamiento convencional para

Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor, according to a new study published today in The New England Journal of Medicine.

… Wednesday, June 18, 2025 Event-free survival (EFS) was 27% higher for patients with locally advanced head and neck squamous cell cancer (HNSCC) who received standard-of-care with neoadjuvant and adjuvant pembrolizumab compared to the control group who did not receive the immune checkpoint inhibitor,